Real-time Soundprism

[EN] This paper presents a parallel real-time sound source separation system for decomposing an audio signal captured with a single microphone in so many audio signals as the number of instruments that are really playing. This approach is usually known as Soundprism. The application scenario of the system is for a concert hall in which users, instead of listening to the mixed audio, want to receive the audio of just an instrument, focusing on a particular performance. The challenge is even greater since we are interested in a real-time system on handheld devices, i.e., devices characterized by both low power consumption and mobility. The results presented show that it is possible to obtain real-time results in the tested scenarios using an ARM processor aided by a GPU, when this one is present.This work has been supported by the "Ministerio de Economia y Competitividad" of Spain and FEDER under projects TEC2015-67387-C4-{1,2,3}-R.Muñoz-Montoro, AJ.; Ranilla, J.; Vera-Candeas, P.; Combarro, EF.; Alonso-Jordá, P. (2019). Real-time Soundprism. The Journal of Supercomputing. 75(3):1594-1609. https://doi.org/10.1007/s11227-018-2703-0S15941609753Alonso P, Cortina R, Rodríguez-Serrano FJ, Vera-Candeas P, Alonso-González M, Ranilla J (2017) Parallel online time warping for real-time audio-to-score alignment in multi-core systems. J Supercomput 73:126. https://doi.org/10.1007/s11227-016-1647-5Carabias-Orti JJ, Cobos M, Vera-Candeas P, Rodríguez-Serrano FJ (2013) Nonnegative signal factorization with learnt instrument models for sound source separation in close-microphone recordings. EURASIP J Adv Signal Process 2013:184. https://doi.org/10.1186/1687-6180-2013-184Carabias-Orti JJ, Rodriguez-Serrano FJ, Vera-Candeas P, Canadas-Quesada FJ, Ruiz-Reyes N (2015) An audio to score alignment framework using spectral factorization and dynamic time warping. In: 16th International Society for Music Information Retrieval Conference, pp 742–748Díaz-Gracia N, Cocaña-Fernández A, Alonso-González M, Martínez-Zaldívar FJ, Cortina R, García-Mollá VM, Alonso P, Ranilla J (2014) NNMFPACK: a versatile approach to an NNMF parallel library. In: Proceedings of the 2014 International Conference on Computational and Mathematical Methods in Science and Engineering, pp 456–465Díaz-Gracia N, Cocaña-Fernández A, Alonso-González M, Martínez-Zaldívar FJ, Cortina R, García-Mollá VM, Vidal AM (2015) Improving NNMFPACK with heterogeneous and efficient kernels for $$\beta$$ β -divergence metrics. J Supercomput 71:1846–1856. https://doi.org/10.1007/s11227-014-1363-yDriedger J, Grohganz H, Prätzlich T, Ewert S, Müller M (2013) Score-informed audio decomposition and applications. In: Proceedings of the 21st ACM International Conference on Multimedia, pp 541–544Duan Z, Pardo B (2011) Soundprism: an online system for score-informed source separation of music audio. IEEE J Sel Top Signal Process 5(6):1205–1215Duong NQ, Vincent E, Gribonval R (2010) Under-determined reverberant audio source separation using a full-rank spatial covariance model. IEEE Trans Audio Speech 18(7):1830–1840. https://doi.org/10.1109/TASL.2010.2050716Ewert S, Müller M (2011) Estimating note intensities in music recordings. In: Proceedings of the IEEE International Conference on Acoustics, Speech, and Signal Processing, pp 385–388Ewert S, Pardo B, Mueller M, Plumbley MD (2014) Score-informed source separation for musical audio recordings: an overview. IEEE Signal Process Mag 31:116–124. https://doi.org/10.1109/MSP.2013.2296076Fastl H, Zwicker E (2007) Psychoacoustics. Springer, BerlinGanseman J, Scheunders P, Mysore GJ, Abel JS (2010) Source separation by score synthesis. Int Comput Music Conf 2010:1–4Goto M, Hashiguchi H, Nishimura T, Oka R (2002) RWC music database: popular, classical and jazz music databases. In: ISMIR, vol 2, pp 287–288Goto M (2004) Development of the RWC music database. In: Proceedings of the 18th International Congress on Acoustics (ICA 2004), ppp 553–556Hennequin R, David B, Badeau R (2011) Score informed audio source separation using a parametric model of non-negative spectrogram. In: 2011 IEEE International Conference on Acoustics, Speech and Signal Processing (ICASSP) pp 45–48. https://doi.org/10.1109/ICASSP.2011.5946324Itoyama K, Goto M, Komatani K et al (2008) Instrument equalizer for query-by-example retrieval: improving sound source separation based on integrated harmonic and inharmonic models. In: ISMIR. https://doi.org/10.1136/bmj.324.7341.827Marxer R, Janer J, Bonada J (2012) Low-latency instrument separation in polyphonic audio using timbre models. In: International Conference on Latent Variable Analysis and Signal Separation, pp 314–321Miron M, Carabias-Orti JJ, Janer J (2015) Improving score-informed source separation for classical music through note refinement. In: ISMIR, pp 448–454Ozerov A, Févotte C (2010) Multichannel nonnegative matrix factorization in convolutive mixtures for audio source separation. IEEE Trans Audio Speech Lang Process 18:550–563. https://doi.org/10.1109/TASL.2009.2031510Ozerov A, Vincent E, Bimbot F (2012) A general flexible framework for the handling of prior information in audio source separation. IEEE Trans Audio Speech Lang Process 20:1118–1133. https://doi.org/10.1109/TASL.2011.2172425Pätynen J, Pulkki V, Lokki T (2008) Anechoic recording system for symphony orchestra. Acta Acust United Acust 94:856–865. https://doi.org/10.3813/AAA.918104Raphael C (2008) A classifier-based approach to score-guided source separation of musical audio. Comput Music J 32:51–59. https://doi.org/10.1162/comj.2008.32.1.51Rodriguez-Serrano FJ, Duan Z, Vera-Candeas P, Pardo B, Carabias-Orti JJ (2015) Online score-informed source separation with adaptive instrument models. J New Music Res 44:83–96. https://doi.org/10.1080/09298215.2014.989174Rodriguez-Serrano FJ, Carabias-Orti JJ, Vera-Candeas P, Martinez-Munoz D (2016) Tempo driven audio-to-score alignment using spectral decomposition and online dynamic time warping. ACM Trans Intell Syst Technol 8:1–20. https://doi.org/10.1145/2926717Sawada H, Araki S, Makino S (2011) Underdetermined convolutive blind source separation via frequency bin-wise clustering and permutation alignment. IEEE Trans Audio Speech Lang Process 19(3):516–527. https://doi.org/10.1109/TASL.2010.2051355Vincent E, Araki S, Theis F et al (2012) The signal separation evaluation campaign (2007–2010): achievements and remaining challenges. Signal Process 92:1928–1936. https://doi.org/10.1016/j.sigpro.2011.10.007Vincent E, Bertin N, Gribonval R, Bimbot F (2014) From blind to guided audio source separation: how models and side information can improve the separation of sound. IEEE Signal Process Mag 31:107–115. https://doi.org/10.1109/MSP.2013.229744

2013. Documento Sevilla de Consenso sobre Alternativas a la Transfusión de Sangre Alogénica. Actualización del Documento Sevilla

La transfusión de sangre alogénica (TSA) no es inocua, y como consecuencia han surgido múltiples alternativas a la misma (ATSA). Existe variabilidad respecto a las indicaciones y buen uso de las ATSA. Dependiendo de la especialidad de los médicos que tratan a los pacientes, el grado de anemia, la política transfusional, la disponibilidad de las ATSA y el criterio personal, estas se usan de forma variable. Puesto que las ATSA tampoco son inocuas y pueden no cumplir criterios de coste-efectividad, la variabilidad en su uso es inaceptable. Las sociedades españolas de Anestesiología y Reanimación (SEDAR), Hematología y Hemoterapia (SEHH), Farmacia Hospitalaria (SEFH), Medicina Intensiva y Unidades Coronarias (SEMICYUC), Trombosis y Hemostasia (SETH) y Transfusiones Sanguíneas (SETS) han elaborado un documento de consenso para el buen uso de la ATSA. Un panel de expertos de las 6 sociedades ha llevado a cabo una revisión sistemática de la literatura médica y elaborado el 2013. Documento Sevilla de Consenso sobre Alternativas a la Transfusión de Sangre Alogénica. Solo se contempla las ATSA dirigidas a disminuir la transfusión de concentrado de hematíes. Se definen las ATSA como toda medida farmacológica y no farmacológica encaminada a disminuir la transfusión de concentrado de hematíes, preservando siempre la seguridad del paciente. La cuestión principal que se plantea en cada ítem se formula, en forma positiva o negativa, como: «La ATSA en cuestión reduce/no reduce la tasa transfusional». Para formular el grado de recomendación se ha usado la metodología Grades of Recommendation Assessment, Development and Evaluation (GRADE)

Foro de debate: seguridad de las alternativas a la transfusión alogénica en el paciente quirúrgico y/o crítico

Estos últimos años han aparecido alertas de seguridad, no siempre bien sustentadas, que cuestionan el uso de algunas alternativas farmacológicas a la transfusión de sangre alogénica y/o lo restringen en indicaciones establecidas. Asistimos también a la preconización de otras alternativas, incluyendo productos hemáticos y fármacos antifibrinolíticos, sin que haya una base científica sólida que lo justifique. Por iniciativa del Grupo de Estudios Multidisciplinares sobre Autotransfusión y del Anemia Working Group Espana¿ se reunió a un panel multidisciplinar de 23 expertos del área de cuidados de la salud en un foro de debate para: 1) analizar las diferentes alertas de seguridad en torno a ciertas alternativas a la transfusión; 2) estudiar los antecedentes que las han propiciado, la evidencia que las sustentan y las consecuencias que conllevan para la práctica clínica, y 3) emitir una valoración argumentada de la seguridad de cada alternativa a la transfusión cuestionada, según el uso clínico de la misma. Los integrantes del foro mantuvieron contactos por vía telemática y una reunión presencial en la que presentaron y discutieron las conclusiones sobre cada uno de los elementos examinados. Se elaboró un primer documento que fue sometido a 4 rondas de revisión y actualización hasta alcanzar un consenso, unánime en la mayoría de los casos. Presentamos la versión final del documento, aprobada por todos los miembros del panel, esperando sea de utilidad para nuestros colegas

Analysis of ancestral and functionally relevant CD5 variants in systemic lupus erythematosus patients

OBJECTIVE: CD5 plays a crucial role in autoimmunity and is a well-established genetic risk factor of developing RA. Recently, evidence of positive selection has been provided for the CD5 Pro224-Val471 haplotype in East Asian populations. The aim of the present work was to further analyze the functional relevance of non-synonymous CD5 polymorphisms conforming the ancestral and the newly derived haplotypes (Pro224-Ala471 and Pro224-Val471, respectively) as well as to investigate the potential role of CD5 on the development of SLE and/or SLE nephritis. METHODS: The CD5 SNPs rs2241002 (C/T; Pro224Leu) and rs2229177 (C/T; Ala471Val) were genotyped using TaqMan allelic discrimination assays in a total of 1,324 controls and 681 SLE patients of Spanish origin. In vitro analysis of CD3-mediated T cell proliferative and cytokine response profiles of healthy volunteers homozygous for the above mentioned CD5 haplotypes were also analyzed. RESULTS: T-cell proliferation and cytokine release were significantly increased showing a bias towards to a Th2 profile after CD3 cross-linking of peripheral mononuclear cells from healthy individuals homozygous for the ancestral Pro224-Ala471 (CC) haplotype, compared to the more recently derived Pro224-Val471 (CT). The same allelic combination was statistically associated with Lupus nephritis. CONCLUSION: The ancestral Ala471 CD5 allele confers lymphocyte hyper-responsiveness to TCR/CD3 cross-linking and is associated with nephritis in SLE patients

Spanish Consensus Statement on alternatives to allogeneic blood transfusion: the 2013 update of the 'Seville Document'

Summary of recommendations on alternatives to reduce allogeneic blood transfusion (in descending order of strength)..

Functional insights into the infective larval stage of Anisakis simplex s.s., Anisakis pegreffii and their hybrids based on gene expression patterns

List of species and specimen used in the phylogenetic tree of Additional file 1. Code of the voucher specimen and accession number for mitochondrial gene COII (*: sequences obtained from GenBank). Labeled are the specimens selected for RNA sequencing (first number, population; second number specimen). A. simplex s.s. – A. pegreffii refers to hybrids haplotype according Abollo et al. [23]. (DOCX 47 kb

Compreendendo o sofrimento humano frente à doença: manifestações, contexto e estratégias

The aim of this study is to understand the suffering of a patient with an illness, by using a secondary research method, that is, a qualitative meta-study. The primary data source of the meta-study includes “biographical reports”. This project is based on a case study, in which the first-hand experiences of a patient with an illness were collected. The findings of the reports were compiled using the Archivos de la Memoria collection of the Index Foundation (Granada, Spain) and journals specialized in editing these materials. A selection of 20 biographical reports was targeted. The results of the meta-study show that suffering is a multidimensional process within a framework of ambiguous feelings. The suffering involves family and social network participation. Patients develop a range of strategies to overcome the illness. One of the effects is the fear of illness relapse or worsening.El propósito de este trabajo es comprender la experiencia del padecimiento ante la enfermedad mediante la utilización de un método de investigación secundaria, un meta estudio cualitativo. La fuente de datos primarios ha sido el relato biográfico, un diseño basado en el estudio de caso que recoge la experiencia en primera persona, en este caso, ante la enfermedad; la localización de relatos se ha hecho a través del fondo Archivos de la Memoria de la Fundación Index y de revistas especializadas en la edición de estos materiales. Se seleccionaron 20 relatos biográficos. Los resultados del meta estudio muestran que el padecimiento es un proceso multidimensional, caracterizado por la ambigüedad de sentimientos. Es un fenómeno que comparte la familia y la red social. Las personas enfermas desarrollan diferentes estrategias de afrontamiento y es manifiesto el miedo a la recaída o el empeoramiento

Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study

Background: Approval of hypomethylating agents in patients with chronic myelomonocytic leukaemia is based on trials done in patients with myelodysplastic syndromes. We aimed to investigate whether hypomethylating agents provide a benefit in subgroups of patients with chronic myelomonocytic leukaemia compared with other treatments. Methods: For this retrospective cohort study, data were retrieved between Nov 30, 2017, and Jan 5, 2019, from 38 centres in the USA and Europe. We included non-selected, consecutive patients diagnosed with chronic myelomonocytic leukaemia, who received chronic myelomonocytic leukaemia-directed therapy. Patients with acute myeloid leukaemia according to 2016 WHO criteria at initial diagnosis (ie, ≥20% blasts in the bone marrow or peripheral blood) or with unavailability of treatment data were excluded. Outcomes assessed included overall survival, time to next treatment, and time to transformation to acute myeloid leukaemia. Analyses were adjusted by age, sex, platelet count, and Chronic myelomonocytic leukaemia-Specific Prognostic Scoring System (CPSS). Patients were grouped by first received treatment with either hydroxyurea, hypomethylating agents, or intensive chemotherapy, and stratified by risk according to blast count, French-American-British subtype, CPSS, WHO 2016 subtype, and the eligibility criteria of the DACOTA trial (NCT02214407). Findings: 949 patients diagnosed with chronic myelomonocytic leukaemia between April 13, 1981, and Oct 26, 2018, were included. Median follow-up was 23·4 months (IQR 11·5–42·3) from diagnosis and 16·2 months (6·6–31·6) from start of first-line treatment. 412 (43%) of 949 patients received hypomethylating agents as first treatment, 391 (41%) hydroxyurea, and 83 (9%) intensive chemotherapy. Adjusted median overall survival for patients treated with hydroxyurea versus hypomethylating agents was 15·6 months (95% CI 13·1–17·3) versus 20·7 months (17·9–23·4); hazard ratio (HR) 1·39 (1·17–1·65; p=0·0002) and 14·0 months (9·8–17·2) versus 20·7 months (17·9–23·4; HR 1·55 [1·16–2·05]; p=0·0027) for those treated with intensive chemotherapy versus hypomethylating agents. In patients with myeloproliferative chronic myelomonocytic leukaemia (myeloproliferative CMML), median overall survival was 12·6 months (10·7–15·0) versus 17·6 months (14·8–21·5; HR 1·38 [1·12–1·70]; p=0·0027) for patients treated with hydroxyurea versus hypomethylating agents, and 12·3 months (8·4–16·6) versus 17·6 months (14·8–21·5; HR 1·44 [1·02–2·03]; p=0·040) for intensive chemotherapy versus hypomethylating agents. Hypomethylating agents did not confer an overall survival advantage for patients classified as having lower-risk disease (ie, myelodysplastic chronic myelomonocytic leukaemia with <10% blasts, CMML-0, or lower-risk CPSS). Interpretation: These data suggest hypomethylating agents as the preferred therapy for patients with higher-risk chronic myelomonocytic leukaemia and those with myeloproliferative CMML. Our findings also suggest that CPSS is a valuable tool to identify patients who are most likely to benefit from hypomethylating agents. Further evidence from prospective cohorts would be desirable. Funding: The Austrian Group for Medical Tumor Therapy. © 2021 Elsevier Lt